Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TRAX with free AI briefings, catalyst countdowns, and dilution alerts.

TRAX · First Tracks Biotherapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$155.6M Cash on Hand
19.1mo Cash Runway
Follow TRAX by email Get an email when TRAX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TRAX, unsubscribe in one click. Privacy

📣 What TRAX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

TRAX holds $155.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.5M/quarter from operations, an estimated runway of 19.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 6 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRAX files for a raise →

👥 Who Owns TRAX

Insiders 19.2% Other 5%+ holders 6.9% Institutions (225 holders) 73.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
EcoR1 Capital, LLC
10% owner
Insider 7,880,094 18.75% 2026-04-20
FMR LLC Institution (13G, 5%+) 6,302,672 15.00% 2026-10-30
Chen Yu 5%+ holder (13G) 2,895,304 6.89% 2026-06-30
BlackRock, Inc. Institution (13G, 5%+) 2,558,473 6.09% 2026-09-30
Sirenia Capital Management LP Institution (13G, 5%+) 2,495,777 5.94% 2026-06-30
Adage Capital Management, L.P. Institution (13G, 5%+) 2,077,179 4.94% 2026-09-30
Affinity Asset Advisors, LLC Institution (13G, 5%+) 2,032,012 4.84% 2026-06-30
Paul F. Lizzul
Chief Medical Officer · +786,461 options
Insider 42,669 0.10% 2026-04-20
John P. Schmid
Director · +7,000 options
Insider 37,652 0.09% 2026-06-15
Rita Jain
Director · +7,000 options
Insider 19,194 0.05% 2026-06-15
John A Orwin
Director · +7,000 options
Insider 17,995 0.04% 2026-09-15
Benjamin Stone
Chief Business Officer · +279,151 options
Insider 17,262 0.04% 2026-04-20

Share count 42,017,901 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TRAX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRAX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.